Molecular genetics of intraductal papillary-mucinous neoplasms of the pancreas.
Intraductal papillary-mucinous neoplasms of the pancreas show characteristic clinicopathological and molecular pathobiological features which are distinct from those of conventional ductal adenocarcinomas. Alterations of KRAS, AKT/PKB, CDKN2A, TP53, SMAD4, STK11/LKB1, and DUSP6, and other molecular alterations, including global expression studies as well as their clinical implications, are discussed.
Furukawa
Toru
T
International Research and Educational Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo 162-8666, Japan.
D002288:Adenocarcinoma, Mucinous / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000231:Adenocarcinoma, Papillary / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D021441:Carcinoma, Pancreatic Ductal / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D004273:DNA, Neoplasm / Q000235:genetics*; D018450:Disease Progression; D054642:Dual Specificity Phosphatase 6 / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D010190:Pancreatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D051901:Smad4 Protein / Q000235:genetics / Q000378:metabolism
D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; C497796:SMAD4 protein, human; D051901:Smad4 Protein; C517035:DUSP6 protein, human; D054642:Dual Specificity Phosphatase 6